Results 21 to 30 of about 6,793 (233)

PD1-3-6: Gene expession prolifing of large cell neuroendocrine carcinoma (LCNEC) [PDF]

Journal of Thoracic Oncology, 2007
Noriko Motoi, Toru Motoi, William L. Gerald, William D. Travis   +3 more
openalex   +2 more sources

A Case of Large Cell Neuroendocrine Carcinoma of the Bladder With Long-Term Control by Metastasectomy. [PDF]

IJU Case Rep
ABSTRACT Introduction Large cell neuroendocrine carcinoma (LCNEC) of the bladder is rare and aggressive. Reports of metastasectomy for single distant metastases are even rarer. Case Presentation A 49‐year‐old man was admitted to our hospital with gross hematuria.
Takaoka N, Kobayashi K, Yamane T, Hiramatsu K, Tsuchihashi K, Kawanishi H, Yamashiro H, Nakayama T, Okumura K.   +8 more
europepmc   +2 more sources

Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report

Frontiers in Oncology, 2023
Large-cell neuroendocrine carcinoma (LCNEC) is a rare subtype of non-small-cell lung cancer associated with a poor prognosis. LCNEC is genetically heterogeneous, and studies have revealed distinct molecular subtypes of LCNEC, which may have therapeutic ...
Aakriti Arora, Jacob Zaemes, Metin Ozdemirli, Chul Kim   +3 more
doaj   +1 more source

Pulmonary large-cell neuroendocrine carcinoma (LCNEC) [PDF]

European Journal of Cardio-Thoracic Surgery, 2003
The experiences on the treatment of seven consecutive patients with large-cell neuroendocrine carcinoma (LCNEC) were studied, observed over 6 years from 1992. Since LCNEC was recognized as a separate histological entity, only very few series have been reported. Together with the carcinoids (atypical and typical) and the small-cell lung carcinoma (SCLC),
René, Hage, Kees, Seldenrijk, Peter, de Bruin, Henry, van Swieten, Jules, van den Bosch   +4 more
openaire   +2 more sources

Pulmonary large cell carcinoma with neuroendocrine morphology shows genetic similarity to large cell neuroendocrine carcinoma

Diagnostic Pathology, 2022
Background Large cell neuroendocrine carcinoma (LCNEC) is a high-grade malignant pulmonary neuroendocrine tumour. The distinction of pulmonary large cell carcinoma (LCC) and LCNEC is based on the presence of neuroendocrine morphology and the expression ...
Zuoyu Liang, Weiya Wang, Qianrong Hu, Ping Zhou, Ying Zhang, Yuan Tang, Qian Wu, Yiyun Fu, Xue Li, Yang Shao, Lili Jiang   +10 more
doaj   +1 more source

Comparative Study of Pulmonary Combined Large-Cell Neuroendocrine Carcinoma and Combined Small-Cell Carcinoma in Surgically Resected High-Grade Neuroendocrine Tumors of the Lung

Frontiers in Oncology, 2021
ObjectivesPulmonary large-cell neuroendocrine carcinoma (LCNEC) and small-cell lung cancer (SCLC) are both classified as pure and combined subtypes. Due to the low incidence and difficult diagnosis of combined LCNEC (C-LCNEC) and combined SCLC (C-SCLC ...
Yanan Wang, Fangfei Qian, Ya Chen, Zhengyu Yang, Minjuan Hu, Jun Lu, Yanwei Zhang, Wei Zhang, Lei Cheng, Baohui Han   +9 more
doaj   +1 more source

Prevalence of TP-53/Rb-1 Co-Mutation in Large Cell Neuroendocrine Carcinoma

Frontiers in Oncology, 2021
IntroductionLarge cell neuroendocrine carcinoma (LCNEC) is a rare and highly aggressive high-grade neuroendocrine neoplasm, which can arise from anywhere in the body.
Hoda Saghaeiannejad Esfahani, Cory M. Vela, Aman Chauhan, Aman Chauhan   +3 more
doaj   +1 more source

Molecular Pathology of Pulmonary Large Cell Neuroendocrine Carcinoma: Novel Concepts and Treatments

Frontiers in Oncology, 2021
Pulmonary large cell neuroendocrine carcinoma (LCNEC) is an aggressive neoplasm with poor prognosis. Histologic diagnosis of LCNEC is not always straightforward.
Masayo Yoshimura, Kurumi Seki, Andrey Bychkov, Andrey Bychkov, Junya Fukuoka, Junya Fukuoka   +5 more
doaj   +1 more source

Molecular Landscape of TP53/RB1 Co-Altered Tumors Uncovers Emerging Therapeutic Vulnerabilities. [PDF]

Genes Chromosomes Cancer
ABSTRACT Background Although TP53 and RB1 co‐alterations play critical roles in promoting malignant development and progression, specific inhibitors targeting this co‐alteration are lacking. We performed a pan‐cancer analysis to characterize the biology of TP53/RB1 co‐alterations and identify therapeutic strategies.
Li X, Ye M, Huang X, Huang ZY, Zhu J, He Z, Zhao Z, Hou J, Wei S.   +8 more
europepmc   +2 more sources

Molecular Characterization and Prognostication of Large Cell Neuroendocrine Carcinoma and Large Cell Carcinoma

Frontiers in Oncology, 2022
PurposeLarge cell neuroendocrine carcinoma (LCNEC) and classic large cell carcinoma (LCC) are two distinct entities with different histological and biological characteristics. However, the mutational profiles and the clinical behavior of the two subtypes
Ying Chen, Xiaoying Cui, Di Wang, Guojie Xia, Minyan Xing, Lei Cheng, Liming Sheng, Xianghui Du   +7 more
doaj   +1 more source